Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
m |
|||
| Line 20: | Line 20: | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Phosphodiesterase inhibitors]] | [[Category:Phosphodiesterase inhibitors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1997]] | ||
Revision as of 15:00, 3 November 2014
Also known as Xagrid.
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]